department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Yervoy · pharmadog

pharmadog
drugs
Yervoy

drug

patient view →

ipilimumab

Marketedupdated 2mo ago

by Bristol-Myers Squibb Co

Approved

community read0 votes

indications

investigational

NSCLC

all catalysts(2)

phase 2 completion · 2

phase 2 completion

National Cancer Institute US — ipilimumab (Phase II Trial Completion)

phase 2 completion

BioCanRx — ipilimumab (Phase II Trial Completion)

News(0)

no news has mentioned this drug yet

brand

Yervoy

generic

ipilimumab

indication

Esophageal Squamous Cell Carcinoma (ESCC)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

tagOncology6 co-mentions · 2 sources
tagNephrology3 co-mentions · 1 sources
companyNational Cancer Institute US1 co-mentions · 1 sources
companyBioCanRx1 co-mentions · 1 sources

Trials studying ipilimumab

phase2Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.recruitingn=138
phase2First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancernot yet recruitingn=26
phase2Pan Tumor Rollover Studyrecruitingn=1,500
phase1A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)completedn=26
phase3MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesotheliomaactive not recruitingn=861
phase2Cryotherapy With in Situ Immunotherapy in Melanoma Metastasiscompletedn=19
phase2Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancerrecruitingn=224
phase2IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanomaterminatedn=8

more trials →